Sarah Mazzilli
Postdoctoral Fellow
Boston University School of Medicine




Investigating the molecular events associated with the progression of premalignant squamous lung lesions for targeted chemoprevention.

Lung cancer kills more than 160,000 individuals in the United States annually. Reduction of lung cancer mortality may be achieved by identification at high risk of developing cancer in addition to effective cancer preventive agents. There has been limited success of candidate chemopreventive agents as most have been assessed in pre-clinical models that do not represent the precancerous and early stage lesions that are examined in clinical chemoprevention trials for lung cancer. Clinical chemoprevention trials in lung cancer often examine the effects of agents on premalignant squamous lesions in patients at risk as such lesions can be regularly monitored by bronchoscopy. My interests and work in the Spira/ Lenburg laboratory involve developing models to aid in the understanding of the molecular events that involved in the progression of premalignant squamous lesions to frank squamous cell carcinoma to identify targets and appropriate models for intervention studies. Utilizing the computational expertise to the group. I am working to further characterize the N-Nitrosotris- (2-chloroethyl) urea chemically induced mouse model of lung squamous cell carcinoma as a model of premalignancy to be used for chemoprevention studies.
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Beane J, Mazzilli SA, Tassinari AM, Liu G, Zhang X, Liu H, Buncio AD, Dhillon SS, Platero SJ, Lenburg ME, Reid ME, Lam S, Spira AE. Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression. Clin Cancer Res. 2017 Sep 01; 23(17):5091-5100.View Related Profiles. PMID: 28533227.
  2. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. 2017 Apr 01; 77(7):1510-1541.View Related Profiles. PMID: 28373404; DOI: 10.1158/0008-5472.CAN-16-2346;.
  3. Campbell JD, Mazzilli SA, Reid ME, Dhillon SS, Platero S, Beane J, Spira AE. The Case for a Pre-Cancer Genome Atlas (PCGA). Cancer Prev Res (Phila). 2016 Feb; 9(2):119-24.View Related Profiles. PMID: 26839336; DOI: 10.1158/1940-6207.CAPR-16-0024;.
  4. Mazzilli SA, Hershberger PA, Reid ME, Bogner PN, Atwood K, Trump DL, Johnson CS. Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model. Cancer Prev Res (Phila). 2015 Oct; 8(10):895-904. PMID: 26276745; PMCID: PMC4664525; DOI: 10.1158/1940-6207.CAPR-14-0403;.
  5. McDowell GS, Gunsalus KT, MacKellar DC, Mazzilli SA, Pai VP, Goodwin PR, Walsh EM, Robinson-Mosher A, Bowman TA, Kraemer J, Erb ML, Schoenfeld E, Shokri L, Jackson JD, Islam A, Mattozzi MD, Krukenberg KA, Polka JK. Shaping the Future of Research: a perspective from junior scientists. F1000Res. 2014; 3:291. PMID: 25653845; DOI: 10.12688/f1000research.5878.1;.

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 5 publications over 4 distinct years, with a maximum of 2 publications in 2017

YearPublications
20141
20151
20161
20172
Contact for Mentoring:


75 E. Newton St Evans Building
Boston MA 02118
Google Map


Mazzilli's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_